| Dr Heena R Chollera, PHARMD | |
|
209 E Commonwealth Ave Apt F, Alhambra, CA 91801-6194 | |
| (909) 802-0978 | |
| Not Available |
| Full Name | Dr Heena R Chollera |
|---|---|
| Gender | Female |
| Speciality | Pharmacist |
| Location | 209 E Commonwealth Ave Apt F, Alhambra, California |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1013472562 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | 77264 (California) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Heena R Chollera, PHARMD 209 E Commonwealth Ave Apt F, Alhambra, CA 91801-6194 Ph: (909) 802-0978 | Dr Heena R Chollera, PHARMD 209 E Commonwealth Ave Apt F, Alhambra, CA 91801-6194 Ph: (909) 802-0978 |
News Archive
Exposure to a single pro-smoking media message increases college-aged students' risk of using tobacco for seven days, providing new clues about the influence of media on smoking, according to a new RAND Corporation study.
Two studies presented today at the Alzheimer's Association International Conference 2012 (AAIC 2012) in Vancouver provide evidence of connections between mild cognitive impairment (MCI) and negative health outcomes – increased isolation and death.
Tyco International Ltd. today reported $0.55 in diluted earnings per share (EPS) from continuing operations for the fiscal fourth quarter of 2010 and diluted EPS from continuing operations before special items of $0.74 per share. Revenue in the quarter was $4.5 billion with organic revenue growth of 2% year-over-year. Cash from operating activities was $963 million and free cash flow was $598 million. These amounts included $39 million of cash outflows related to restructuring activities and acquisition-related costs.
ALLOZYNE, Inc. announced today, the completion of its first Phase IA clinical trial in healthy individuals for AZ01, a PEGylated form of human interferon beta-1b which is being developed for the treatment of relapsing remitting multiple sclerosis. The objectives of the Phase IA trial were to assess safety and tolerability profile in addition to defining its pharmacological properties.
› Verified 1 days ago
Phuong Lien Ngo, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 69 E Main St, Alhambra, CA 91801 Phone: 626-300-8049 | |
Dr. Andrew Duong, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 211 S Curtis Ave Apt E, Alhambra, CA 91801 Phone: 626-800-8883 | |
Raymond T Chan, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 69 E Main St, Alhambra, CA 91801 Phone: 626-300-8047 | |
Chia Fang Chang, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 88 S Garfield Ave Unit 128, Alhambra, CA 91801 Phone: 240-687-2659 | |
Dru Elizabeth Lezina, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1000 S Fremont Ave, Alhambra, CA 91803 Phone: 855-885-2600 | |
Angela Hyunjung Choi, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 305 N 3rd St Apt B, Alhambra, CA 91801 Phone: 626-542-5415 |